US4485101A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Peptides
Assignee: Tulane University
•
Filing: 1983-10-11
•
Granted: 1984-11-27
•
Expires: 2003-10-11
Abstract
Abstract In one aspect, dodecapeptides capable of inhibiting GH, insulin, and glucagon secretion and having the formula N-acetyl-Cys-Lys-Asn-A-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-B-NH.sub.2 wherein A is Phe or 4-X-Phe wherein X is Cl, Br, or F, and B is Cys or D-Cys; or a pharmaceutically acceptable salt thereof.
Inventors
- 👤 David H. Coy
- 👤 William A. Murphy
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 14:46
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/655; C07K14/6555; A; A61; A61P; A61P5/00; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/16
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
37 words
A dodecapeptide of the formula: N-acetyl-Cys-Lys-Asn-A-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-B-NH 2 wherein A is Phe or 4-X-Phe wherein X is Cl, Br, or F, and B is Cys or D-Cys; its cyclic 1-12 disulfide analog; or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
37 words
A dodecapeptide of the formula: N-acetyl-Cys-Lys-Asn-A-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-B-NH 2 wherein A is Phe or 4-X-Phe wherein X is Cl, Br, or F, and B is Cys or D-Cys; its cyclic 1-12 disulfide analog; or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
24 words
The dodecapeptide of claim 1 wherein A is 4-Cl-Phe and B is Cys; its cyclic 1-12 disulfide analog; or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
24 words
The dodecapeptide of claim 1 wherein A is 4-Cl-Phe and B is D-Cys; its cyclic 1-12 disulfide analog; or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
32 words
A therapeutic composition capable of inhibiting the release of growth hormone, insulin, or glucagon comprising a therapeutically effective amount of the compound of claim 1 together with a pharmaceutically acceptable carrier substance.
Claim 6
Dependent Claim
32 words
A method of treating a mammal in need of reduction of growth hormone, insulin, or glucagon secretion comprising administering to said mammal a therapeutically effective amount of the compound of claim 1.
Claim 7
Dependent Claim
31 words
The therapeutic composition of claim 4 wherein said composition is in the form of a pill, tablet, or capsule for oral administration to a human patient in need of said compound.
Claim 8
Dependent Claim
28 words
The therapeutic composition of claim 4 wherein said composition is in the form of a liquid for oral administration to a human patient in need of said compound.
Claim 9
Dependent Claim
50 words
The therapeutic composition of claim 6, said composition being coated with a substance capable of protecting said composition from the gastric acid in the stomach of said human patient for a period of time sufficient to allow said composition to pass undisintegrated into the small intestine of said human patient.
Claim 10
Dependent Claim
33 words
The therapeutic composition of claim 4, said composition being in the form of a cream, gel, spray, or ointment for application to the skin of a human patient in need of said compound.
Claim 11
Dependent Claim
33 words
The therapeutic composition of claim 4, said composition being in the form of a liquid capable of being administered nasally as drops or spray to a human patient in need of said compound.
Claim 12
Dependent Claim
31 words
The therapeutic composition of claim 4, said composition being in the form of a liquid for intravenous, subcutaneous, parenteral, or intraperitoneal administration to a human patient in need of said compound.
Claim 13
Dependent Claim
24 words
The dodecapeptide of claim 1 wherein A is Phe and B is Cys; its cyclic 1-12 disulfide analog; or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
US4133782A
Cited
US4211693A
Cited
US4190575A
Cited
US4224199A
Cited
US4215039A
Cited
US4209426A
Cited
US4369179A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-11-27 | 1988-05-28 | 1988-11-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-11-27 | 1992-05-28 | 1992-11-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-11-27 | 1996-05-28 | 1996-11-27 | $7700.00 | Window Closed / Lapsed |